In this retrospective analysis aiming to identify an ultra-low-risk subgroup of patients with multiple myeloma who may benefit from stopping therapy, which combination of features defined that subgroup?
ISS stage I–II, genomic standard risk by the updated consensus classification, and MRD negativity at a sensitivity of at least 10⁻⁶ by NGS, sustained for 24 months
ISS stage I only, absence of 1q gain, and MRD negativity at 10⁻⁵ by next-generation flow, sustained for 12 months
Any ISS stage, genomic standard risk, and PET-CT negativity alone, sustained for 5 years off therapy